SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

14 Aug 2023 Evaluate
The sales moved up 27.17% to Rs. 2954.67 millions for the June 2023 quarter as compared to Rs. 2323.32 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 167.23% to Rs. 538.60  millions  from Rs. 201.55 millions in previous same quarter.Operating Profit saw a handsome growth to 753.49 millions from 320.78 millions in the quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 2954.67 2323.32 27.17 2954.67 2323.32 27.17 10029.71 8056.00 24.50
Other Income 81.04 41.14 96.99 81.04 41.14 96.99 261.02 147.58 76.87
PBIDT 753.49 320.78 134.89 753.49 320.78 134.89 1914.27 1009.33 89.66
Interest 1.54 1.86 -17.20 1.54 1.86 -17.20 8.33 9.47 -12.04
PBDT 751.95 318.92 135.78 751.95 318.92 135.78 1503.65 999.86 50.39
Depreciation 37.98 45.92 -17.29 37.98 45.92 -17.29 162.60 169.49 -4.07
PBT 713.97 273.00 161.53 713.97 273.00 161.53 1341.05 830.37 61.50
TAX 175.37 71.45 145.44 175.37 71.45 145.44 348.12 214.43 62.35
Deferred Tax 0.70 -5.29 -113.23 0.70 -5.29 -113.23 -34.90 -11.86 194.27
PAT 538.60 201.55 167.23 538.60 201.55 167.23 992.93 615.94 61.21
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 25.50 13.81 84.70 25.50 13.81 84.70 19.09 12.53 52.34

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×